Kasamon YL, et al. - A prospective trial of nonmyeloablative HLA-haploidentical (NMA haplo) blood or marrow transplantation (BMT) for patients with hematologic malignancies (median age, 61), evaluating the safety of early discontinuation of tacrolimus. With this platform of haplo BMT, stopping tacrolimus as early as day 60 was feasible. Shortened-duration tacrolimus might reduce relapse and enable earlier or more effective posttransplantation therapies for relapse reduction.